|
Spatial proximity of CD8 T cells to tumor cells as an independent biomarker for response to anti-PD-1 therapy. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars |
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures |
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |